#United States #Burlington #financial results #revenue growth #Labcorp

Labcorp Reports Strong Q3 Results for 2025

Labcorp Holdings Inc. (NYSE: LH), renowned for its innovative laboratory services, has announced its financial results for the third quarter of 2025, exhibiting significant growth and strategic advancements. The company reported revenues amounting to $3.56 billion, an increase from $3.28 billion in the same period of 2024, marking an 8.6% rise. Its diluted earnings per share (EPS) also soared to $3.12, up from $2.00 a year earlier.

CEO Adam Schechter expressed confidence in the company’s trajectory. He noted, “Labcorp's third-quarter performance reflects continued momentum in our Diagnostics and Central Laboratory businesses, resulting in strong revenue growth and margin improvement.” The strategic maneuvers in specialty testing areas, particularly in oncology and neurology, have also added to the company's progress.

Moreover, Labcorp has raised its guidance for the full year 2025. The revenue outlook now stands at a growth range of 7.4% to 8.0%, slightly lowered by 40 basis points due to currency fluctuations and acquisition timing. The adjusted EPS guidance has been revised to $16.15 to $16.50, showcasing an increase to the midpoint by $0.05. Additionally, expected free cash flow is projected between $1.17 billion and $1.29 billion, with insights suggesting a positive upward shift of $25 million in the midpoint.

Strategic Partnerships and Growth in Specialty Testing

In its quest to expand its healthcare collaborations, Labcorp has successfully signed several strategic agreements with health systems and regional laboratories. Notably, the company is responsible for growth in high-value specialty testing segments through new partnerships and acquisitions. Highlights include:

• - The acquisition of select assets from Empire City Laboratories, aiming to strengthen services in the New York Tri-State area.
• - An agreement with Laboratory Alliance of Central New York for pathology reference laboratory assets.
• - Progress on acquiring assets from Community Health Systems across 13 states and the completion of acquisition from BioReference Health, enhancing Labcorp’s oncology capabilities.

Innovative Advancements

Labcorp has further integrated cutting-edge technologies and innovative solutions within its operations this quarter. Key accomplishments include:

• - OmniSeq® INSIGHT now assesses ovarian tumors for homologous recombination deficiency, reinforcing its robust oncology portfolio.
• - The first tissue-based tumor profiling test, PGDx elio™, received CE-marking under the EU’s In Vitro Diagnostic Regulation.
• - The acquisition of FDA approval for Geneoscopy’s ColoSense®, a streamlined, at-home RNA-based colorectal cancer screening test.
• - Enhanced access to genetic tests via a new collaboration with Epic, improving the ordering and results delivery process.
• - The introduction of two new Alzheimer's tests aimed at both specialty and primary care settings in neurology.
• - Significant expansions in the consumer space through Labcorp OnDemand, which has launched several new tests.

In terms of digital and operational enhancements, Labcorp unveiled the Labcorp Test Finder, improving customer experience. Investments in Artificial Intelligence technologies are ongoing to streamline lab processes in pathology, cytology, and microbiology.

Financial Summary and Future Projections

As of the end of the third quarter, Labcorp maintained a solid financial position with a cash balance of $598 million and total debt of $5.58 billion. The company’s operating cash flow reached $387.2 million, a stark increase from $277.3 million in Q3 2024. Free cash flow experienced a healthy rise to $280.5 million, up from $161.5 million.

Additionally, Labcorp's Board of Directors has declared a quarterly cash dividend of $0.72 per share, set for distribution to shareholders in December 2025. The company also executed a share repurchase of $25 million, demonstrating its commitment to returning value to shareholders.

As Labcorp continues to elevate its platform through strategic alignment and technological incorporation, the final quarter of 2025 poses a promising outlook as the company remains determined to deliver substantial value to both clients and shareholders alike. For more insights, Labcorp invites investors to tune into its conference call regarding this quarter's results.

Conclusion: As Labcorp gears up for the final quarter of 2025, the successful Q3 performance reflects a proactive approach towards expanding partnerships and leveraging technology, paving the way for continued growth in the healthcare sector.